Correlation between the erbB family gene mutation and clinico-pathological factors, in lung cancer.

肺癌中erbB家族基因突变与临床病理因素的相关性。

基本信息

批准号：
18390381
负责人：
SASAKI Hidefumi
金额：
$ 7.78万
依托单位：
Nagoya City University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2006
资助国家：
日本
起止时间：
2006 至 2007
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18390381/
关键词：
EGFR Molecular Target Gefitinib Lung Cancer ErbB3 ErbB4 ゲフィチニブ erbB2

项目摘要

Epidermal growth factor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib were approver for treatment of lung cancers. In 2004, we collaborated with Dana Farber Cancer Institute and found the EGFR somatic mutations at kinase domain from lung cance samples. The mutations were correlated with gefitinib sensitivity in vitro and in vivo. We have established the sensitive genotyping assays (Taq-Man; Lung cancer : 2005: 50: 375-384 and LightCycler; Cl in Cancer Res: 2005: 11: 2924-2929) to detect these EGFR mutations from clinical samples. Using these assays, we have evaluated the mutation status and clinico-pathological background. We have also evaluated the EGFR mutations at exon 20, as known as resistant mutant for gefitinib therapy. We have also performed the FISH analysis to examine the EGFR amplification status. ErbB3 and erbB4 expression and mutation were also examined, however, we did not find and erbB3 or erbB4 mutation. We have cont inued the collaboration with Dana Farber Cancer Institute and using the SNP array, we examined the gene mutation statuses for large scale lung cancer samples. The results were published at Nature Genetics (2007: 39: 347-351)

表皮生长因子（EGFR）酪氨酸激酶抑制剂，吉非替尼和厄洛替尼是治疗肺癌的批准者。 2004年，我们与Dana Farber癌症研究所合作，发现了来自肺Cance样品的激酶域的EGFR体细胞突变。突变与吉非替尼在体外和体内的敏感性相关。我们已经建立了敏感的基因分型测定（TAQ-MAN；肺癌：2005：50：375-384和Lightcycler; CLANCEN in Cancer Res：2005：11：2924-2929）从临床样品中检测这些EGFR突变。使用这些测定，我们评估了突变状态和临床病理背景。我们还评估了外显子20的EGFR突变，称为吉法替尼治疗的抗性突变体。我们还进行了鱼类分析以检查EGFR扩增状态。还检查了ERBB3和ERBB4的表达和突变，但是，我们没有发现和ERBB3或ERBB4突变。我们已经与Dana Farber Cancer Institute合作，并使用SNP阵列，研究了大规模肺癌样本的基因突变状态。结果发表在《自然遗传学》（2007：39：347-351）上

项目成果

期刊论文数量（0）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung

DOI：
10.1016/j.lungcan.2006.09.003
发表时间：
2007-01-01
期刊：
LUNG CANCER
影响因子：
5.3
作者：
Sasaki, Hidefumi;Endo, Katsuhiko;Fujii, Yoshitaka
通讯作者：
Fujii, Yoshitaka

EGFR exon 20 insertion mutation in Japanese lung cancer

DOI：
10.1016/j.lungcan.2007.06.024
发表时间：
2007-12-01
期刊：
LUNG CANCER
影响因子：
5.3
作者：
Sasaki, Hidefumi;Endo, Katsuhiko;Fujii, Yoshitaka
通讯作者：
Fujii, Yoshitaka

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

DOI：
10.1073/pnas.0510284103
发表时间：
2006-05-16
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
影响因子：
11.1
作者：
Ji, Hongbin;Zhao, Xiaojun;Wong, Kwok-Kin
通讯作者：
Wong, Kwok-Kin

ErbB4 expression and mutation in Japanese patients with lung cancer